Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Doxycycline is a safe alternative to Hydroxychloroquine + Azithromycin to prevent clinical worsening and hospitalization in mild COVID-19 patients: An open label randomized clinical trial (DOXYCOV)

View ORCID ProfileEugene Sobngwi, Sylvain Zemsi, Magellan Guewo-Fokeng, Jean-Claude Katte, Charles Kounfack, Liliane Mfeukeu-Kuate, Armel Zemsi, Yves Wasnyo, Antoinette Assiga Ntsama, Arnaud Ndi-Manga, Joelle Sobngwi-Tambekou, William Ngatchou, Charlotte Moussi Omgba, Jean Claude Mbanya, Pierre Ongolo Zogo, Pierre Joseph Fouda
doi: https://doi.org/10.1101/2021.07.25.21260838
Eugene Sobngwi
1Yaounde Central Hospital, Yaounde, Cameroon
2Faculty of Medicine and Biomedical Sciences, University of Yaounde 1, Yaounde, Cameroon
3RSD Institute, Yaounde, Cameroon
4The Biotechnology Centre, University of Yaounde 1, Yaounde, Cameroon
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Eugene Sobngwi
  • For correspondence: eugene.sobngwi@fmsb-uy1.cm
Sylvain Zemsi
1Yaounde Central Hospital, Yaounde, Cameroon
3RSD Institute, Yaounde, Cameroon
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Magellan Guewo-Fokeng
2Faculty of Medicine and Biomedical Sciences, University of Yaounde 1, Yaounde, Cameroon
3RSD Institute, Yaounde, Cameroon
4The Biotechnology Centre, University of Yaounde 1, Yaounde, Cameroon
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jean-Claude Katte
2Faculty of Medicine and Biomedical Sciences, University of Yaounde 1, Yaounde, Cameroon
3RSD Institute, Yaounde, Cameroon
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Charles Kounfack
1Yaounde Central Hospital, Yaounde, Cameroon
5Faculty of Medicine and Pharmaceutical Sciences, University of Dschang, Dschang, Cameroon
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Liliane Mfeukeu-Kuate
1Yaounde Central Hospital, Yaounde, Cameroon
2Faculty of Medicine and Biomedical Sciences, University of Yaounde 1, Yaounde, Cameroon
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Armel Zemsi
1Yaounde Central Hospital, Yaounde, Cameroon
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yves Wasnyo
1Yaounde Central Hospital, Yaounde, Cameroon
3RSD Institute, Yaounde, Cameroon
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Antoinette Assiga Ntsama
1Yaounde Central Hospital, Yaounde, Cameroon
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Arnaud Ndi-Manga
1Yaounde Central Hospital, Yaounde, Cameroon
3RSD Institute, Yaounde, Cameroon
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Joelle Sobngwi-Tambekou
3RSD Institute, Yaounde, Cameroon
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
William Ngatchou
6Faculty of Medicine and Pharmaceutical Sciences, University of Douala, Douala, Cameroon
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Charlotte Moussi Omgba
7Regional Delegation of Public Health, Centre Region, Ministry of Public Health, Cameroon
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jean Claude Mbanya
1Yaounde Central Hospital, Yaounde, Cameroon
2Faculty of Medicine and Biomedical Sciences, University of Yaounde 1, Yaounde, Cameroon
4The Biotechnology Centre, University of Yaounde 1, Yaounde, Cameroon
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Pierre Ongolo Zogo
1Yaounde Central Hospital, Yaounde, Cameroon
2Faculty of Medicine and Biomedical Sciences, University of Yaounde 1, Yaounde, Cameroon
8Center for the Development of Good Practices in Health, Yaounde, Cameroon
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Pierre Joseph Fouda
1Yaounde Central Hospital, Yaounde, Cameroon
2Faculty of Medicine and Biomedical Sciences, University of Yaounde 1, Yaounde, Cameroon
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Data/Code
  • Preview PDF
Loading

Abstract

Objective We aimed to compare the safety and efficacy of a doxycycline-based regimen against the national standard guidelines (Hydroxychloroquine plus Azithromycin) for the treatment of mild symptomatic COVID-19.

Methods We conducted an open-label, randomized, non-inferiority trial, in Cameroon comparing Doxycycline 100mg, twice daily for 7 days versus Hydroxychloroquine, 400 mg daily for 5 days and Azithromycin 500mg at day 1 and 250mg from day 2 through 5, in mild COVID-19 patients. Clinical improvement, biological parameters and adverse events were assessed. The primary outcome was the proportion of clinical cure at day 3, 10 and 30. Non-inferiority was determined by the clinical cure rate between protocols with a 20 percentage points margin.

Results 194 participants underwent randomization and were treated with Doxycycline (n=97) or Hydroxychloroquine-Azithromycin (n=97). At day 3, 74/92 (80.4%) participants on Doxycycline versus 77/95 (81.1%) on Hydroxychloroquine-Azithromycin -based protocols were asymptomatic (p=0.91). At day 10, 88/92 (95.7%) participants on Doxycycline versus 93/95 (97.9%) on Hydroxychloroquine-Azithromycin were asymptomatic (p=0.44). At day 30 all participants were asymptomatic. SARS-CoV2 PCR was negative at Day 10 in 60/92 (65.2%) participants allocated to Doxycycline and 63/95 (66.3%) participants allocated to Hydroxychloroquine-Azithromycin. None of the participants were admitted for worsening of the disease after treatment initiation.

Conclusion Doxycycline 100 mg twice daily for 7 days is as effective and safe as Hydroxychloroquine-Azithromycin, for preventing clinical worsening of mild symptomatic or asymptomatic COVID-19, and achieving virological suppression.

Strengths and Limitations

  • ➢ This study is one of the first randomized trial, assessing the efficacy and tolerance of Doxycycline to treat COVID-19

  • ➢ It is one of the first to evaluate disease progression and need to hospitalization in mild or asymptomatic COVID-19

  • ➢ Patients will not receive identical treatments

  • ➢ Doxycycline has advantages in terms of availability, safety and cost compared to Hydroxychloroquine and Azytromycin

  • ➢ Though this study has encounter 7 lost to follow-up, this does not have a major influence on our results

  • ➢ These data will assist clinicians in their daily practice, and provide a new tool for the fight against COVID-19

Competing Interest Statement

The authors have declared no competing interest.

Clinical Trial

NCT04715295

Funding Statement

The study was partially sponsored by a special grant from the French Embassy in Cameroon. The study benefited of material support from the RSD institute Yaounde Cameroon and Yaounde Central Hospital.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

The study received ethical clearance from the Cameroon National Ethics Committee (2020/07/1585/L/CNERSH/SP).

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Data Availability

Data availability is subject to prior approval by the National Ethics Committee of Cameroon and the Minister of Public Health

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-ND 4.0 International license.
Back to top
PreviousNext
Posted July 29, 2021.
Download PDF
Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Doxycycline is a safe alternative to Hydroxychloroquine + Azithromycin to prevent clinical worsening and hospitalization in mild COVID-19 patients: An open label randomized clinical trial (DOXYCOV)
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Doxycycline is a safe alternative to Hydroxychloroquine + Azithromycin to prevent clinical worsening and hospitalization in mild COVID-19 patients: An open label randomized clinical trial (DOXYCOV)
Eugene Sobngwi, Sylvain Zemsi, Magellan Guewo-Fokeng, Jean-Claude Katte, Charles Kounfack, Liliane Mfeukeu-Kuate, Armel Zemsi, Yves Wasnyo, Antoinette Assiga Ntsama, Arnaud Ndi-Manga, Joelle Sobngwi-Tambekou, William Ngatchou, Charlotte Moussi Omgba, Jean Claude Mbanya, Pierre Ongolo Zogo, Pierre Joseph Fouda
medRxiv 2021.07.25.21260838; doi: https://doi.org/10.1101/2021.07.25.21260838
Digg logo Reddit logo Twitter logo Facebook logo Google logo LinkedIn logo Mendeley logo
Citation Tools
Doxycycline is a safe alternative to Hydroxychloroquine + Azithromycin to prevent clinical worsening and hospitalization in mild COVID-19 patients: An open label randomized clinical trial (DOXYCOV)
Eugene Sobngwi, Sylvain Zemsi, Magellan Guewo-Fokeng, Jean-Claude Katte, Charles Kounfack, Liliane Mfeukeu-Kuate, Armel Zemsi, Yves Wasnyo, Antoinette Assiga Ntsama, Arnaud Ndi-Manga, Joelle Sobngwi-Tambekou, William Ngatchou, Charlotte Moussi Omgba, Jean Claude Mbanya, Pierre Ongolo Zogo, Pierre Joseph Fouda
medRxiv 2021.07.25.21260838; doi: https://doi.org/10.1101/2021.07.25.21260838

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Pharmacology and Therapeutics
Subject Areas
All Articles
  • Addiction Medicine (179)
  • Allergy and Immunology (431)
  • Anesthesia (99)
  • Cardiovascular Medicine (942)
  • Dentistry and Oral Medicine (178)
  • Dermatology (109)
  • Emergency Medicine (260)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (418)
  • Epidemiology (8969)
  • Forensic Medicine (4)
  • Gastroenterology (418)
  • Genetic and Genomic Medicine (1938)
  • Geriatric Medicine (190)
  • Health Economics (400)
  • Health Informatics (1322)
  • Health Policy (657)
  • Health Systems and Quality Improvement (517)
  • Hematology (211)
  • HIV/AIDS (416)
  • Infectious Diseases (except HIV/AIDS) (10769)
  • Intensive Care and Critical Care Medicine (570)
  • Medical Education (199)
  • Medical Ethics (52)
  • Nephrology (221)
  • Neurology (1818)
  • Nursing (108)
  • Nutrition (271)
  • Obstetrics and Gynecology (351)
  • Occupational and Environmental Health (469)
  • Oncology (992)
  • Ophthalmology (296)
  • Orthopedics (111)
  • Otolaryngology (182)
  • Pain Medicine (126)
  • Palliative Medicine (44)
  • Pathology (265)
  • Pediatrics (576)
  • Pharmacology and Therapeutics (275)
  • Primary Care Research (234)
  • Psychiatry and Clinical Psychology (1891)
  • Public and Global Health (4109)
  • Radiology and Imaging (674)
  • Rehabilitation Medicine and Physical Therapy (363)
  • Respiratory Medicine (547)
  • Rheumatology (224)
  • Sexual and Reproductive Health (190)
  • Sports Medicine (177)
  • Surgery (206)
  • Toxicology (38)
  • Transplantation (109)
  • Urology (80)